(Pharmamar) PharmaMar (MSE:PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.
PharmaMar has requested the process of re-examination for Aplidin® from the EMA
Please login to join discussion
POPULAR NEWS
-
Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps
-
ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy
-
New Study Suggests ALS and MS May Stem from Common Environmental Factor
-
Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission